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Abstract
Fibromyalgia (FM) is characterized by chronic widespread pain whose pathophysiological mechanism is related to central and
peripheral nervous system dysfunction. Neuropathy of small nerve fibers has been implicated due to related pain descriptors,
psychophysical pain, and neurophysiological testing, as well as skin biopsy studies. Nevertheless, this alteration alone has not been
previously associated to the dysfunction in the descending pain modulatory system (DPMS) that is observed in FM. We hypothesize
that they associated, thus, we conducted a cross-sectional exploratory study.
To explore small fiber dysfunction using quantitative sensory testing (QST) is associated with the DPMS and other surrogates of
nociceptive pathways alterations in FM.
We run a cross-sectional study and recruited 41 women with FM, and 28 healthy female volunteers. We used the QST to measure
the thermal heat threshold (HTT), heat pain threshold (HPT), heat pain tolerance (HPT), heat pain tolerance (HPTo), and conditional
pain modulation task (CPM-task). Algometry was used to determine the pain pressure threshold (PPT). Scales to assess
catastrophizing, anxiety, depression, and sleep disturbances were also applied. Serum brain-derived neurotrophic factor (BDNF)
was measured as a marker of neuroplasticity. We run multivariate linear regression models by group to study their relationships.
Samples differed in their psychophysical profile, where FM presented lower sensitivity and pain thresholds. In FM but not in the
healthy subjects, regression models revealed that serum BDNF was related to HTT and CPM-Task (Hotelling Trace=1.80, P< .001,
power=0.94,R2=0.64). HTTwas directly related to CPM-Task (B=0.98, P= .004, partial-n2=0.25), and to HPT (B=1.61, P= .008,
partial n2=0.21), but not to PPT. Meanwhile, BDNF relationship to CPM-Task was inverse (B=–0.04, P= .043, partial-n2=0.12), and
to HPT was direct (B=–0.08, P= .03, partial-n2=0.14).
These findings high spot that in FM the disinhibition of the DPMS is positively correlated with the dysfunction in peripheral sensory
neurons assessed by QST and conversely with serum BDNF.
Abbreviations: ACR = American College of Rheumatology, BDI-II = Beck Depression Inventory, BDNF = brain-derived
neurotrophic factor, BP-PCS = Brazilian Portuguese Catastrophizing Scale, CPM-task = conditional pain modulation task, DPMS =
descending pain modulatory system, ELISA = Enzyme-Linked Immunosorbent Assay, FIQ = Fibromyalgia Impact Questionnaire, FM
= Fibromyalgia, HCPA = Hospital de Clinicas de Porto Alegre, HPT = heat pain threshold, HPTO = heat pain tolerance, HTT =
thermal heat threshold, LTD = long term depression, NGF = neural growth factor, NMDA = N-methyl-D-aspartate, NPS = numerical
pain scale, NRM = nucleus raphe magnus, PKC = Protein kinase C, PPT = pain pressure threshold, PSQI = Pittsburgh Sleep Quality
Index, QST= quantitative sensory testing, STAI= State-Trait Anxiety Inventory, STT= spinothalamic tract, tDCS= transcranial directEditor: Devrimsel Harika Ertem.
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sensory testing1. Introduction
Fibromyalgia (FM) is a syndrome that comprises chronic
widespread pain, usually described as occurring in deep somatic
tissues (i.e., in muscles and joints), accompanied by fatigue,
circadian rhythm disturbances, anxiety, depression, and pain
catastrophizing.[1] Patients present high distress, functional
disability, bowel/bladder irritability, and abnormal pain sensi-
tivity for pressure and thermal stimuli,[2] often described as
burning or prickling sensations. Recently, a growingly accepted
pathophysiological model for fibromyalgia attributes central and
peripheral nervous system alterations (both functional and
anatomical) as responsible for the wide spectrum of the clinical
picture.[3]
To understand the potential role of the peripheral nervous
system involvement in fibromyalgia, it is relevant to address the
nociception physiology. Sensitivities to warmth and cold involve
specific fibers, which has a range of average resting skin
temperatures (25–35 °C). These fibers are activated by threshold
stimuli that fire low-threshold afferent fibers, which converges to
nociceptive spinothalamic tract (STT) neurons. These convergent
stimuli are associated with nerve injury, and can induce selective
apoptosis of inhibitory GABAergic inter-neurons.[4] This pro-
cesses decreased the inhibitory receptors expression (on primary
afferent terminals and postsynaptic neurons)[5] and it culminates
with a higher perception of repetitive nociceptive stimuli, that is,
temporal and spatial summation.[6,7] Both phenomena comprise
a primarymechanism of the pathophysiology of neuropathic pain
syndromes, but it also has been pointed out as a possible
mechanism in FM.
A sizeable multicenter cohort study compared sensory
symptoms of fibromyalgia with painfuldiabetic neuropathy
and it found that both conditions share similar descriptors to
characterize the sensorial perceptions (i.e., the pain of burning
quality, a prickling sensation, and the existence of touch-
evoked).[8] Although in FM there are signs of “small fiber
neuropathy,” the relationship between nerve conduction findings
or biopsies and the severity of pain-related symptoms is
incongruent.[9] In fact, the peripheral nociception modulates
the central nervous system (CNS), and the level of dysfunction in
peripheral sensorial fibers could be linked to the imbalance of
excitability/inhibitory pain pathways. Also, this process involves
the high-affinity of brain-derived neurotrophic factor (BDNF) to
the trkB receptor, which enhances C fiber-evoked responses,
strengthening excitatory (glutamatergic), and weakening inhibi-
tory (GABAergic) synapses.[10] Accordingly, a study in rats under
persistent pain, at nucleus raphe magnus (NRM), the BDNF-K+–
Cl–cotransporter (KCC2)-GABA induced a shift in the potential
gradient chlorine currents, such that the inhibitory GABA-A
currents become excitatory.[11]
This neurotrophic factor contributes to decreased pain
threshold in FM patients and central sensitization augmenta-
tion.[12,13] It is involved in the disinhibition process related to the
loss of the descending pain inhibitory pathways and with the2
increase in intracortical facilitation (as indexed by transcranial
magnetic stimulation).[12,13] Additionally, it is associated with
severity and clinical course of mood disorders[14] and it predicted
effect of therapeutic approaches involving changes in the
neuroplasticity state, as the transcranial direct current stimula-
tion (tDCS) in cognitive in FM.[15]
Taking this into account; we hypothesize that the dysfunction
of small peripheral fibers could be related to the dysfunction of
descending pain modulatory system in FM. Thus, we conducted
this exploratory study to examine if small fiber dysfunction in FM
is linked to a malfunction in the descending pain modulatory
system. To test this hypothesis, we run 3 different tests: we used
the QST to measure the thermal heat threshold (HTT), the heat
pain threshold (HPT), and the heat pain tolerance (HPT). Also,
the QST was used to assess the change in Numerical Pain Scale
(NPS0–10) during a conditional pain modulation task (CPM-
task). While the algometry was used to determine the pain
pressure threshold (PPT).2. Methods
2.1. Study design
This exploratory study was conducted at one single center in
Hospital de Clínicas de Porto Alegre (Rio Grande do Sul, Brazil)
during 2016 to 2017, and recruited patients with fibromyalgia,
and controls with no pain. The protocol was reviewed and
approved by the Ethics Committee Board of the Hospital de
Clínicas de Porto Alegre (Institutional Review Board IRB
0000921) in accordance with the Declaration of Helsinki. All
subjects gave their written informed consent before participation.
2.1.1. Design overview, setting, and participants. In this
cross-sectional study, women, aged between 18 and 60 years,
were recruited from local community care units, an institutional
chronic pain clinic, by referrals from other hospital units, and by
phone and newspaper. FM sample selection considered the
American College of Rheumatology criteria for fibromyalgia.[16]
A physician with >15 years of experience in pain clinic, and
highly skilled at diagnosing chronic pain conditions, re-examined
patients and then re-confirmed their diagnosis. FM patients were
included if they had experienced pain scored in the numerical
pain scale (NPS 0–10)≥5 (i.e., moderate or severe pain) in the last
3 months. Additionally, the pain should be associated with
disability, as assessed by an affirmative answer to dichotomous
questions (yes/no) of a structured questionnaire. The queries
inquired if their pain had interfered with work; enjoyable
activities; responsibilities at home; relationships; personal goals;
and thinking clearly, problem-solving, concentrating, or recall.
We excluded patients with a rheumatic or neurologic condition
such as stroke or Parkinson disease; the habitual use of
corticosteroids; or other uncompensated chronic disease. We
excluded patients with any malignancy diagnosis, human
immunodeficiency virus, or if they were illiterate.
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general population by advertisement postings in the universities,
on the internet, and in public places in the Porto Alegre area.
Subjects were considered eligible to participate if they were
women, ranging between 19 and 60 years age. They answered a
structured questionnaire that assessed the following variables:
current acute or chronic pain conditions, use of analgesics in the
past week, rheumatologic disease, clinically significant or
unstable medical or psychiatric disorder, history of alcohol or
substance abuse in the past 6 months, neuropsychiatric
comorbidity, and use of psychotropic drugs. They were excluded
if answered positively to any of these questions, or if they
presented scores ≥13 in the Beck Depression Inventory (BDI-
II).[17] Unlike the patient sample, none of the control volunteers
underwent a physical examination.
2.2. Instruments and assessments
2.2.1. Outcomes and measurements. The primary outcome
was the score on NPS (0–10) during the conditioned pain
modulated (CPM-Task). The secondary outcomes were the
temperature in the quantitative sensory testing (QST) to provoke
pain score 6 on the NPS (0–10); the pain pressure threshold
(PPT). The primary factor of interest was the thermal thresholds
determination induced by the QST. It was assessed as surrogate
for small fibers dysfunction involved in pain and thermal
processing, and is described in detail below.(a) Quantitative Sensory Testing (QST): all subjects underwent
a standardized protocol performed in a single session, by the
same researcher. A single training session was offered before
so participants could get familiar with the device. All subjects
were oriented to keep the eyes closed during the examination
and to be concentrated in the stimuli applied. The QST was
used to measure the thermal thresholds determination (TTD)
and heat pain threshold (HPT). The assessment used the
method of limits with a computer Peltier-based device
thermode (30X30mm)[18] in a computer Peltier-based device
using the method of limits. It was attached to the skin on the
ventral aspect of the mid-forearm. The QST was set at 32°C
and temperature was increased at a rate of 1°C/s to a
maximum of 52°C. To define the TTD and HPT on each
patient, the mean of three assessments was calculated (inter-
stimuli interval of 40seconds).[18] The thermode position was
slightly altered between trials to avoid sensitization and
response suppression of cutaneous heat nociceptors. TheQST
was used to determine the temperature needed to induce a
mild pain (6/10 on the NPS), and was defined as the mean
of three assessments with an inter-stimuli interval of
40seconds.[18] The maximum tolerated temperature was
also determined, and named Heat Pain Tolerance (HPTO),
with a single trial (no previous training neither repetitions
allowed). Patients were asked to press the digital indicate
when experiencing the maximal heat perception they could
tolerate.
To measure the CPM-task we evaluated the pain intensity in(b)
two tonic HPT test stimuli separated by an intense
heterotopic pain stimulation. We used the HPT as condition-
ing pain stimulus to elicit a prolonged pain sensation to
trigger CPM. The CPM-task consisted of three steps. First,
we stimulated the dominant forearm with augmenting
temperature until previously determined to obtain moderate
pain (6/10 in the NPS), and asked again the NPS attributed to
it. This temperature was maintained constant during the task.3
Then (more precisely, 30s after), the non-dominant hand was
immersed in cold water (temperature of 0–1 °C) during 1
minute. After 30seconds of applying the cold stimulus,
subjects were asked to provide the NPS (0–10) attributed to
the heath stimulus. To maintain the water temperature at 0 to
1 °C we used a thermostat to control the temperature
variation. To determine the CPM we subtracted the NPS
(0–10) after cold stimuli to the one before it (in other works,
NPSafter–NPSbefore cold). If the patients did not report a
reduction or report an increase in their pain score during the
CPM-task, the descendent modulatory systems was consid-
ered to have failed to modulate the nociceptive response.[12]
The pressure pain threshold (PPT) is defined as the minimum(c)
force applied which induces pain. Pressure algometry
measurements were performed to evaluate PPTs in the right
forearm region. The PPT was measured with a digital
algometer (Somedic, Stockholm, Sweden). The pressure was
always manually applied by the same researcher at a rate of
increase of 50kPa/s through a circular rubber-coated pressure
probe (1cm2). Then, subjects were asked to verbalize when
perceiving the first pain. The pressure pain threshold for each
subject was determined with the mean of three right forearm
single-point algometry.
The laboratory outcome measured was the serum level of(d)
BDNF. We collected the 69 blood samples before starting the
assessment. Samples were centrifuged for 10minutes at
4500g at 4 °C, and we stored at –80 °C. Serum BDNF was
determined using an Enzyme-Linked Immunosorbent Assay
(ELISA) using a ChemiKine BDNF Sandwich ELISA Kit,
CYT306 (Chemicon/Millipore, Billerica, MA). The lower
detection limit of the kit for BDNF is 7.8pg/mL.
2.2.2. Other instruments and assessments. All the instru-
ments used to assess psychological state were validated in the
Brazilian population. Two independent medical examiners that
were blinded to the aim of the study were trained to conduct the
psychological tests and to administer the pain scales. Depressive
symptoms were assessed using the Beck Depression Inventory
(BDI-II).[17,19] Pain catastrophizing was assessed using the
Brazilian Portuguese Catastrophizing Scale (BP-PCS)[20] and,
sleep quality with the Pittsburgh Sleep Quality Index (PSQI).[21]
To assess the anxiety, we used the refined version of the State-
Trait Anxiety Inventory (STAI) obtained using the Rasch model,
which was reduced from the state-trait STAI-Form X scales.[22]
The scores in the state- and trait-scales ranges from 13 to 52, and
from 12 to 36, respectively. To evaluate the quality of life we used
the Fibromyalgia Impact Questionnaire (FIQ).[23] The pain
intensity was measured with a 100-mm VAS. The VAS scores
ranged from no pain (0) to worst possible pain (100mm). We
used a standardized questionnaire to assess demographic data
and medical comorbidities.2.3. Sample size
A sample size of 61 subjects would detect an effect size for
correlations of 0.2, with a power of 95% at a 0.05 alpha level for
an effect size (f2=determination coefficient=0.2) for the multiple
hierarchical regression analysis, allowing for 3 predictors. It was
calculated using the Post hoc statistical power calculator for
hierarchical multiple regression at https://www.danielsoper.com/
statcalc/calculator.aspx?id=17. Finally, considering the likely
attrition rate and other unexpected factors, the required sample
size was determined to be 69 patients.
Table 1







Age, y 32.1 (4.56) 49.1 (8.32) <.001
BMI, kg/m2 22.9 (3.3) 29.6 (±6.6) <.001
Level of education, y 16 (2.9) 11.4 (±4.0) <.001
Clinical
Beck Depression Inventory—BDI–II 2.3 (4.12) 24.8 (6.34) <.001
Pain Catastrophizing Scale—PCS 6.1 (4.31) 31.9 (12.02) <.001
State-Trait Anxiety Inventory—STAI
STAI—state 19.0 (3.9) 29.0 (6.4) <.001
STAI—trait 15.2 (3.9) 26.0 (6.6) <.001
Pittsburgh Sleep Quality Index—PSQI 5.57 (3.76) 10.6 (4.91) <.011
Data area presented as mean (standard deviation) (n=69).
∗
Compared using t-test for independent samples.
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Descriptive statistics were used to summarize the main socio-
demographic features the sample. t tests for independent samples
and chi-squared and Fisher exact tests were used to compare
continuous and categorical variables between groups, respective-
ly. To test for normality we used the Shapiro-Wilk test. Because
the BDNF is not normally distributed, we performed a
logarithmic transformation. After verifying the corresponding
assumptions, the Pearson correlation coefficient was used to
assess bivariate relationship between covariates (catastrophizing,
state-trait anxiety, and depressive symptoms) with the outcomes
related to psychophysical measures (CPM-task, HPT, PPT, and
HPTO). To address imbalance between groups (FM and healthy
subjects), that could interfere with the HTT (main interest factor),
we generated a propensity score to reduce or eliminate these effect
in further analysis of the relationship between the HTT and
outcomes. To create the adjusted index of HTT, we run a
regression analysis using the stepwise method to enter the
covariates. The criteria to include the covariates in the model was
to present a P-value <.05. The dependent variable was the HTT,
and the independent variables were years of education, age, the
number of chronic disorders, use of psychotropic medications,
state-anxiety, depressive symptoms, and pain catastrophizing.
The adjusted HTT-index (main interest factor) was used together
with the serum BDNF as independent variables in multivariate
analysis models. To assess their relationship with the dependent
measures (CPM-task—primary outcome) and HPT, PPT, and
HPTO (secondary outcomes), we created a multivariate model
for each group (FM and healthy subjects). Bonferroni correction
for multiple comparisons was applied. Spearman correlation was
used to study the relationship between CPM-task and BDNF, and
HTT. Data were analyzed using SPSS software version 22.0
(SPSS, Chicago, IL).3. Results
3.1. Demographic and clinical characteristics of the
subjects
We screened 75 potential participants with a diagnosis of FM,
and included 41 subjects. We screened 41 potential participants
for the control group (healthy volunteers) and enrolled 28
subjects. The reasons for exclusion were: not fulfilling the
diagnostic criteria for FM, lacking disability as defined in the
protocol, and the presence of another relevant comorbidity (i.e.,Table 2
Pearson (r) correlation between potential confounding factors and o






































State-Trait Anxiety (STAI-S and STAI-T); BDI-II=Beck Depression Inventory II (BDI-II); BP-PCS=Brazilian P
task= change on NPS (0–10) during the conditioned pain modulated; PPT=pain pressure threshold.
∗
Correlation is significant at the 0.05 level (2-tailed).
∗∗
Correlation is significant at the 0.01 level (2-tailed).
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rheumatoid arthritis, previous stroke). The clinical and demo-
graphic characteristics of the subjects are presented in Table 1.3.2. Univariate analysis
3.2.1. Assessment of relationship between psychological
measures and psychophysical parameters. The Pearson
correlation coefficient was used to identify potential confounding
factors in the bivariate relationships between the psychological
and psychophysical measures which comprised our outcomes
(CPM-task, PPT, HPT, HPTO, and HTT, see Table 2).3.3. Psychophysical measures and BDNF by group (FM vs
healthy subjects)
As expected, psychophysical tests presented differences between
the studied groups, see Table 3.
Taking into account that there are differences between FM and
healthy subjects in some factors that can interfere with the HTT
(main factor of interest), we generated a propensity score to
reduce this effect in further analysis, as described in the statistical
analysis section. The adjusted determination coefficient of the
model was R2=0.13, explaining 13% of the variance in the HTT
(standard b coefficient for the state-anxiety=0.46, t=3.02;
standard b coefficient for the pain catastrophizing=0.55, t=
3.33, both P< .01).utcomes (N=69).










r=–0.14 r=–0.05 r=–0.09 r=–0.17
ortuguese Pain Catastrophizing Scale; HTT=heat thermal threshold; HPT=heat pain tolerance; CPM-
Table 3
Psychophysical tests (HTT, PPT, HPT, HPTO, CPM-task) and BDNF by group (n=69).
FM (n=41) Healthy controls (n=28) P-value
∗
Heat thermal thresholds (HTT), °C 33.62 (1.44) 33.82 (1.17) .54
Heat thermal thresholds (HTT-adjusted) 33.81 (0.56) 34.12 (0.34) .01
Pain pressure threshold (PPT), °C 2.44 (0.74) 3.51 (1.11) .001
Heat pain threshold (HPT), °C 39.87 (4.77) 42.24 (3.10) .01
Heat pain tolerance (HPTO), °C 45.49 (3.81) 47.84 (2.20) .002
Change on NPS (0–10) during the (CPM-task) 0.46 (1.92) 3.54 (1.93) .001
Brain-derived neurotrophic factor (BDNF), ng/mL 38.08 (20.78) 16.21 (7.85) .001
Celsius degree (°C); Numerical Pain Scale (NPS 0–10) equal to 6; change on NPS (0–10) during the conditioned pain modulated (CPM-task). Heat thermal threshold (HTT) (adjusted index generate by a regression
analysis).
∗
Comparisons of mean using t test for independent samples.
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HTT-adjusted and psychophysical measures (HPT, HPTO,
HPP) by group
Taking into account that FM and healthy subjects are different in
many aspects, we ran separate multivariate analysis for each
group. Tables 4 and 5 present the result of the multivariate
regression analysis in FM (Table 4) and healthy subjects
(Table 5). The dependent variables were the psychophysical
measures (PPT, HPT, HPTO, CPM-task). The independent
variables were the HTT-adjusted and the BDNF. The multivari-
ate model revealed a significant relationship between the HTT-
adjusted, BDNF, and CPM-Task in FM (Hotelling Trace=1.80,
F [34]=16.23, P< .001), with a power of 0.94, and R2=0.64;
thus, explaining 64% of the variance in the outcome variables
(Table 4). The HTT-adjusted was positively correlated with theTable 4
The relationship between BDNF and HTTP-adjusted index with the
fibromyalgia (n=41).
B. Fibromyalgia group
Dependent variable Type III sum of squares
Change on NPS (0–10) during the CPM-task 52.900a
Pain pressure threshold 0.100b
Heat pain threshold 295.406c
Heat pain tolerance 47.196d
Parameter B Std. error
Change on NPS (0–10) during the CPM-task
Intercept 29.81 10.924
Brain derivate neural factor (BDNF) (log) 0.04 0.020
Heat thermal threshold (adjusted index) 0.98 0.318
Pain pressure threshold
Intercept 4.043 3.696
Brain derivate neural factor (BDNF) (log) 0.001 0.007
Heat thermal threshold (adjusted) 0.04 0.10
Heat pain threshold (HPT)
Intercept 18.73 19.446
Brain derivate neural factor (BDNF) (log) 0.080 0.036
Heat thermal threshold (adjusted) 1.609 0.566
Heat pain tolerance
Intercept 23.445 17.040
Brain derivate neural factor (BDNF) (log) 0.03 0.03
Heat thermal threshold (adjusted) 0.60 0.49
BDNF=brain-derived neurotrophic factor, CPM= conditional pain modulation, NPS=numerical pain sca
a R-squared=0.24 (adjusted R-squared=0.19).
b R-squared=0.005 (adjusted R-squared=–0.06).
c R-squared=0.35 (adjusted R-squared=0.32).
d R-squared=0.10 (adjusted R-squared=0.05).
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CPM-task and with the HPT. Indeed, an increase in their pain
score during the CPM-task indicates the worst function of
descending pain modulatory system. However, the HTT was
correlated neither with the PPT nor with the HPTOL (see
Table 4). On the other hand, these associations were not present
in the healthy control sample (Table 5).
The multiple regression analysis confirmed a positive correla-
tion between the HTT-adjusted with the CPM-task in FM, but
not in the healthy subjects (Table 4). For illustrative purposes the
scatter plot of the HTT-adjusted and CPM-task in fibromyalgia is
presented in Figure 1. The Spearman correlation coefficient (rho)
was 0.35 (confidence interval 95%=0.05–0.59).
Scatter plots of the raw change on NPS (0–10) during CPM-
task and BDNF by group (FM and healthy subjects) are presented
in Figure 2A and B, respectively. We observed an inversepsychophysical outcomes (HPT, HPP, HPT, and CPM-task) in
df Mean square F Sig. Partial-n2
2 26.450 5.885 0.008 0.250
2 0.050 0.080 0.923 0.005
2 147.703 8.610 0.001 0.357
2 23.598 1.791 0.184 0.104
t Sig. CI 95% Partial-n2
2.729 0.010 (–52.09 to –7.53) 0.194
2.068 0.043 (–0.08 to –0.01) 0.121
2.777 0.004 (0.23–1.69) 0.250
1.094 0.283 (–3.49–11.58) 0.037
0.09 0.929 (–0.02–0.02) 0.000
0.40 0.691 (–0.26–0.18) 0.005
0.963 0.343 (–58.39–20.95) 0.029
2.240 0.03 (0.07–0.15) 0.139
2.842 0.008 (0.45–2.76) 0.207
1.376 0.179 (–11.30–58.19) 0.06
1.109 0.276 (–0.03–0.09) 0.04
1.217 0.233 (–0.40–1.61) 0.05
le.
Table 5
The relationship between BDNF and HTTP-adjusted with the psychophysical outcomes (HPT, HPP, HPT, and CPM-task) in healthy
subjects (n=28).
Dependent variable Type III sum of squares df Mean square F Sig. Partial-n2
Change on NPS (0–10) during the CPM-task 17.951a 2 8.976 2.736 0.08 0.18
Pain pressure threshold 5.740b 2 2.870 2.597 0.09 0.17
Heat pain threshold 24.728c 2 12.364 1.308 0.29 0.09
Heat pain tolerance 8.384d 2 4.192 0.854 0.43 0.06
B Std. error t Sig. CI 95% Partial-n2
Change on NPS (0–10) during the CPM-task
Intercept –17.29 13.552 –1.276 0.21 (–45.20–10.62) 0.061
Heat thermal threshold (adjusted index) 0.35 0.39 0.90 0.37 (–0.45–1.15) 0.032






Intercept –12.16 7.865 –1.547 0.134 (–28.36–4.03) 0.087
Heat thermal threshold (adjusted index) 0.438 0.226 1.934 0.065 (–0.03–0.90) 0.130
Brain derivate neural factor (BDNF) (log) 0.040 0.026 1.535 0.137 (–0.02–0.09) 0.086
Heat pain threshold
Intercept 51.219 23.003 2.227 0.035 (3.84–98.59) 0.165
Heat thermal threshold (adjusted index) –0.313 0.662 –0.473 0.640 (–1.68–1.05) 0.009
Brain derivate neural factor (BDNF) (log) 0.110 0.077 1.436 0.163 (–0.05–0.27) 0.076
Heat pain tolerance
Intercept 27.449 16.582 1.655 0.110 (–6.70–61.59) 0.099
Heat thermal threshold (adjusted index) 0.598 0.477 1.252 0.222 (–0.38–1.58) 0.059
Brain derivate neural factor (BDNF) (log) –0.008 0.055 –0.144 0.887 (–0.12–0.10) 0.001
BDNF=brain-derived neurotrophic factor, CPM= conditional pain modulation, NPS=numerical pain scale.
a R-squared=0.180 (adjusted R-squared=0.114).
b R-squared=0.172 (adjusted R-squared=0.106).
c R-squared=0.095 (adjusted R-squared=0.022).
d R-squared=0.064 (Adjusted R-squared=–0.011).
∗
P< .05.
Brietzke et al. Medicine (2019) 98:3 Medicinenonparametric correlation between BDNF and CPM-Task in FM
group (Rho=–0.32, Confidence Interval 95%=0.05–0.59),
suggesting that in FM, the increase of serum BDNF is associated
with stronger function of the descending pain modulatory system
(DPMS), given that higher values in the CPM-Task suggests less
function of the DPMS. In the FM group, 43.9% presented CPM-
task values >0, suggesting a summation effect. Although in the
healthy group no subjects exhibited this phenomenon, we had
observed a positive correlation between the BDNF andCPM-task.Figure 1. Scatterplot of the heat thermal threshold (HTT) and the change on
NPS (0–10) during CPM-task (n=41) in fibromyalgia. CPM=conditional pain
modulation, NPS=numerical pain scale.
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4. Discussion
This study confirmed our hypothesis that the peripheral sensory
dysfunction is associated with the disengagement of the
descending pain modularity system (DPMS) in FM, but not in
healthy subjects. The HTT-adjusted was positively correlated
with the CPM-task. Indeed, an increase in the pain score during
the CPM-task indicates worst function of the DPMS. Further, the
HTT was positively correlated with the BDNF, but not with the
PPT. Also, the FM sample presented lower pain thresholds, for
both heat and pressure.
The current study expanded available data in the scientific
literature showing that the peripheral sensory dysfunction in FM
was associated with the disengagement of the DPMS. This finding
is aligned with previous reports that suggested that in FM exist
greater disinhibition at the cortical level compared with those in
which the primary mechanism of pain was persistent and intense
nociceptive input (i.e., OA).[13] Given the exploratory nature of
our study, we could infer that: either the dysfunction in small
fibers leads to distinct plastic changes in pain modulatory
pathways; or the alterations of the modulatory system induce
small fibers dysfunction; or both processes are consequences of
different phenomena keeping their functioning correlated.
Independently of the mechanisms, our findings speak in favor
of a cross-talk between the peripheral afferent and the neural
network of the spine-bulbospinal loop along with changes in the
BDNF secretion. Thus, this set of changes reinforce the
hypothesis that the disinhibition process is a feature of FM, as
the dysfunctions in excitatory/inhibitory systems in pain path-
ways are nothing but the biological grounds of the clinical picture
known as central sensitization syndrome. Even though this
relationship is complex, our results give neurophysiological
support to link the peripheral dysfunction of small fibers, and the
[32]
Figure 2. Scatterplot of the brain-derived neurotrophic factor (BDNF) and the change on the NPS (0–10) during CPM-task. (A) Fibromyalgia (n=41), and (B) healthy
subjects (N=28). CPM=conditional pain modulation, NPS=numerical pain scale.
Brietzke et al. Medicine (2019) 98:3 www.md-journal.comactivity of the descending inhibitory system with the central
sensitization[24] and higher activation in the brainstem.[25]
The downward negative spiral of pain and the DPMS have
significant implications regarding the nosological status of
FM: small fiber pathology may be a peripheral nervous system
contributor to the complex pathophysiology of pain in
fibromyalgia. Hence, the combination of “lesion of the
somatosensory nervous system” (i.e., fiber loss) and pain defines
“neuropathic pain.”[26] Thus, the pain described by fibromyalgia
patients appears to be closely related to neuropathic pain; which
by definition comprise an identifiable group of signs and
symptoms and a small fiber impairment, which would qualify
fibromyalgia as a disease that deserves to be recognized
accordingly. The HTT assessed by the QST and the heat-pain
thresholds are considered the most useful and specific for
evaluation of a small fiber neuropathy.
Although the QST measures abnormalities in either the central
or peripheral nervous system, both alterations can result in the
same deficit. The QST has been used in many longitudinal studies
and clinical trials to identify neuropathy and is widely
available.[27] Finally, QST is unable to distinguish between
feigned and real loss of sensation.[28] However, the reliability of
the QST is in question to require conscious integration from the
patient and cognitive conditions to comprehend the test (due to
disease or medication).
In the present study patients with FM showed presented with
lower HPT and PPT compared with healthy subjects. Our finding
is in line with previous reports that displayed higher mechanical
pain sensitivity and higher cold pain sensitivity,[29] and lower
heat pain thresholds[30] in FM compared with healthy controls,
using QST, and using CO2-laser stimulation.
[31] Assessment of
laser-evoked potentials in patients with fibromyalgia gave hints
for C-fibers sensitization, and ultra-late laser-evoked potentials7
could be recorded in the majority of patients. In fact, these set
of findings showed conflicting results by not precise reasons, but
on the overall, give support for the concept of the peripheral
neuropathy in the fibromyalgia syndrome.
The small sample size is a limitation of this study, although
significance values and statistical methods were keep within the
conventionally accepted by the scientific literature. The design of
our study limits the ability to determine causality, but still
provides interesting insights that might motivate further research
as it strengthen the notion of peripheral small fiber dysfunction in
FM, effect. The HTT assesses the function in small fibers
indirectly, but still it has been shown to have a relatively precise
measure of the C-fibers function.[26] However, the QST measures
are a useful tool for neurophysiological assessment in using
a non-invasive method, and that showed a great sensibility to
assess peripheral neuropathy. In this study, only women were
evaluated, taking into account that sex differences in pain
perception and modulation are a controversial topic.[33] This
limitation restricts the possibility of a direct comparison with
other studies but has the advantage of avoiding possible
contamination of the data. Because FM is more prevalent in
women,[34] these results might have more considerable clinical
implications. Although we recruited healthy volunteers to assess
the relationship between the cortical inhibitory function and the
PDMS, it is worth noting that our control sample was younger on
average.
According to our results, patients with FM has dysfunctional
pain and increase BDNF levels that may be involved in the
pathophysiology of pain.[35] In the dorsal horn, activation of the
receptors by endogenous BDNF seems to contribute to hyper-
algesia, suggesting that BDNF contributes to the sensitization of
the dorsal neurons (wind up), facilitating the activation of
NMDA receptors. Therefore, acute or chronic stimulation of pain
Brietzke et al. Medicine (2019) 98:3 Medicineimproves the phosphorylation of several receptor subunits
(NMDAR) in the spinal cord.[36,37] The release of BDNF during
pain modulation is mediated by the activation of NMDA
receptors by glutamate, along with substance P, acting as rapid
neurotransmitters and slow modulators at primary pain synap-
ses.[38] In sensory neurons, the concentration of BDNF and
substance P depends on the availability of neurogenic growth
factor (NGF), which is produced in the periphery, reaching the
dorsal ganglia after binding to the trkA receptors of the terminal
fibers containing substance P and BDNF. Studies have shown that
increased NGF in peripheral tissues in inflammatory processes
promote expression of BDNF and substance P in sensory
neurons.[38,39] And inhibition of Trk-B receptor activity can
completely abolish allodynia and thermal hyperalgesia of the
sciatic nerve in neuropathic pain models.[40] Inhibitors of TRK
tyrosine kinase activity and protein kinase C (PKC) inhibitors
also blocked neuropathic pain. Thus, BDNF plays an important
role in the regulation of inflammatory pain and secondary
hyperalgesia, but BDNF released only from nociceptors has no
importance in the development of neuropathic pain.[41]
We found that FMpatients presents an increased pain response
to painful mechanical stimuli, similar to others studies.[42,43]
Comparing healthy subjects and FM patients in heat pain
threshold and tolerance to the heat, FM group have been shown
reduced heat pain threshold and tolerance to heat. Authors
suggested central sensitization as a contributing pathophysiologic
factor.[44,45] Accordingly, wind-up as an experimental correlate
for central sensitization can be evoked in controls and in FM
patients, but clear differences between controls and patients can
be observed. The magnitude of the sensory response to the first
stimulus within a series is greater in FM, as in the amount of
temporal summation within a series.[46]
Our results add to the growing evidence that abnormalities of
cutaneous fiber C pain are related to specific aspects of central
sensitization in FM patients[42] supported by QST, CPM-task,
and PPT. With FM pain, there is increased excitation of the
central neurons that induces rearrangements of the dorsal horn
neurons. All changes are collectively “central sensitization.”[47] A
previous consequence of the peripheral lesion is a spinal
microglial activation leading to a release of brain-derived
neurotrophic factor (BDNF).[48] However, the mechanisms
involved in “central sensitization” remain poorly understood
and the link between pain and BDNF remains unclear. Indeed,
BDNF engaging in acute pain remains controversial. Some data
are consistent with an anti-nociceptive role, while others are
consistent with a pro-nociceptive effect.[49] These authors shown
that blocking signaling between BDNF and the receptor TrkB
reverses the allodynia. And that BDNF is a crucial signaling
molecule between microglia and neurons. Blocking this micro-
glia-neuron signaling pathway may represent a therapeutic
strategy for treating neuropathic pain.[50]
Our results showed that the perception of referred pain when
providing a conditioning stimulus at the same time (CPM task)
applied in the FM group has a loss of inhibitory system function,
as demonstrated in a similar study.[51] To increase the
modulation system of endogenous inhibitory pain during the
CPM task, one study administered melatonin in FM patients and
the authors found positive results.[43] Another study showed that
the CPM-task applied in patients with knee osteoarthritis had
decreased activation of the endogenous pain modulation
system.[51] However, when administered CPM-task in healthy
individuals, the observed response is based on the principle of
pain inhibiting pain.[52] Thus, we observe that in healthy8
individuals, the system of downward modulation of pain is
preserved, maintaining a basal state of sensory processing. And
data support the apparent loss of downward net inhibition as a
mechanism that promotes chronic pain, while inhibition
engagement protects against chronic pain.[53]5. Conclusion
These findings high spot that in FM the disinhibition of the DPMS
is positively correlated with the dysfunction in peripheral sensory
neurons assessed by QST and conversely with serum BDNF.Author contributions
Conceptualization: Wolnei Caumo, Aline Patrícia Brietzke,
Fabiana Carvalho, Felipe Fregni.
Data curation: Aline Patrícia Brietzke, Fabiana Carvalho, Jessica
Elkfury, Paulo Roberto Stefani Sanches, Danton Pereira da
Silva, Jairo Alberto Dussán-Sarria, Andressa Souza.
Formal analysis: Wolnei Caumo, Jairo Alberto Dussán-Sarria.
Funding acquisition: Wolnei Caumo.
Investigation: Aline Patrícia Brietzke, Luciana Conceição
Antunes, Fabiana Carvalho, Jessica Elkfury, Assunta Gas-
parin, Paulo Roberto Stefani Sanches.
Methodology: Wolnei Caumo, Jessica Elkfury, Assunta Gas-
parin, Paulo Roberto Stefani Sanches, Andressa Souza.
Project administration: Wolnei Caumo, Aline Patrícia Brietzke,
Luciana Conceição Antunes, Danton Pereira da Silva,
Andressa Souza.
Resources: Wolnei Caumo, Andressa Souza.
Writing – original draft: Wolnei Caumo, Luciana Conceição
Antunes, Jairo Alberto Dussán-Sarria, Iraci Lucena da Silva
Torres.
Writing – review & editing: Wolnei Caumo, Felipe Fregni.References
[1] Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of
Rheumatology preliminary diagnostic criteria for fibromyalgia and
measurement of symptom severity. Arthritis Care Res (Hoboken)
2010;62:600–10.
[2] Häuser W, Wolfe F, Tölle T, et al. The role of antidepressants in the
management of fibromyalgia syndrome: a systematic review and meta-
analysis. CNS Drugs 2012;26:297–307.
[3] Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic
widespread pain. Neuroscience 2016;338:114–29.
[4] Moore KA, Kohno T, Karchewski LA, et al. Partial peripheral nerve
injury promotes a selective loss of GABAergic inhibition in the superficial
dorsal horn of the spinal cord. J Neurosci 2002;22:6724–31.
[5] Kohno T, Wang H, Amaya F, et al. Bradykinin enhances AMPA and
NMDA receptor activity in spinal cord dorsal horn neurons by activating
multiple kinases to produce pain hypersensitivity. J Neurosci 2008;28:
4533–40.
[6] Staud R, Robinson ME, Price DD. Temporal summation of second pain
and its maintenance are useful for characterizing widespread central
sensitization of fibromyalgia patients. J Pain 2007;8:893–901.
[7] Staud R, Koo E, Robinson ME, et al. Spatial summation of mechanically
evoked muscle pain and painful aftersensations in normal subjects and
fibromyalgia patients. Pain 2007;130:177–87.
[8] Koroschetz J, Rehm SE, Gockel U, et al. Fibromyalgia and neuropathic
pain–differences and similarities. A comparison of 3057 patients with
diabetic painful neuropathy and fibromyalgia. BMCNeurol 2011;11:55.
[9] Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547–55.
[10] Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth
Factors 2004;22:123–31.
[11] Zhang Z, Wang X, Wang W, et al. Brain-derived neurotrophic factor-
mediated downregulation of brainstem K+–Cl– cotransporter and cell-
type–specific GABA impairment for activation of descending pain
facilitation. Mol Pharmacol 2013;8:511–20.
[12] Botelho LM, Morales-Quezada L, Rozisky JR, et al. A framework for [32] Granot M, Buskila D, Granovsky Y, et al. Simultaneous recording of late
Brietzke et al. Medicine (2019) 98:3 www.md-journal.comunderstanding the relationship between descending pain modulation,
motor corticospinal, and neuroplasticity regulation systems in chronic
myofascial pain. Front Hum Neurosci 2016;10:308.
[13] Caumo W, Deitos A, Carvalho S, et al. Motor cortex excitability and
BDNF levels in chronic musculoskeletal pain according to structural
pathology. Front Hum Neurosci 2016;10:357.
[14] Fernandes BS, Gama CS, Maria Ceresér K, et al. Brain-derived
neurotrophic factor as a state-marker of mood episodes in bipolar
disorders: a systematic review and meta-regression analysis. J Psychiatr
Res 2011;45:995–1004.
[15] Santos VSDSD, Zortea M, Alves RL, et al. Cognitive effects of
transcranial direct current stimulation combined with working memory
training in fibromyalgia: a randomized clinical trial. Sci Rep 2018;8:
12477.
[16] Wolfe F, Egloff N, HäuserW.Widespread pain and low widespread pain
index scores among fibromyalgia-positive cases assessed with the 2010/
2011 fibromyalgia criteria. J Rheumatol 2016;43:1743–8.
[17] Warmenhoven F, Van Rijswijk E, Engels Y, et al. The Beck Depression
Inventory (BDI-II) and a single screening question as screening tools for
depressive disorder in Dutch advanced cancer patients. Support Care
Cancer 2012;20:319–24.
[18] Schestatsky P, Stefani LC, Sanches PR, et al. Validation of a Brazilian
quantitative sensory testing (QST) device for the diagnosis of small fiber
neuropathies. Arq Neuropsiquiatr 2011;69:943–8.
[19] Gomes-Oliveira MH, Gorenstein C, Lotufo Neto F, et al. Validation of
the Brazilian Portuguese version of the Beck Depression Inventory-II in a
community sample. Rev Bras Psiquiatr 2012;34:389–94.
[20] Sehn F, Chachamovich E, Vidor LP, et al. Cross-cultural adaptation and
validation of the Brazilian Portuguese Version of the Pain Catastroph-
izing Scale. Pain Med 2012;13:1425–35.
[21] Buysse DJ, Hall ML, Strollo PJ, et al. Relationships between the
Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS),
and clinical/polysomnographic measures in a community sample. J Clin
Sleep Med 2008;4:563–71.
[22] Kaipper MB, Chachamovich E, Hidalgo MPL, et al. Evaluation of the
structure of Brazilian State-Trait Anxiety Inventory using a Rasch
psychometric approach. J Psychosom Res 2010;68:223–33.
[23] Marques AP, Adriana M, Barsante Santos AA, et al. Validation of the
Brazilian Version of the Fibromyalgia Impact Questionnaire (FIQ). Rev
Bras Reum 2006;46:24–31.
[24] Mense S. How do muscle lesions such as latent and active trigger points
influence central nociceptive neurons? J Musculoskelet Pain 2010;18:
348–53.
[25] Mhalla A, de Andrade DC, Baudic S, et al. Alteration of cortical
excitability in patients with fibromyalgia. Pain 2010;149:495–500.
[26] Treede RD. Highly localized inhibition of pain via long-term depression
(LTD). Clin Neurophysiol 2008;119:1703–4.
[27] Peltier A, Smith AG, Russell JW, et al. Reliability of quantitative
sudomotor axon reflex testing and quantitative sensory testing in
neuropathy of impaired glucose regulation. Muscle Nerve 2009;39:
529–35.
[28] Freeman R, Chase KP, Risk MR. Quantitative sensory testing cannot
differentiate simulated sensory loss from sensory neuropathy. Neurology
2003;60:465–70.
[29] Blumenstiel K, Gerhardt A, Rolke R, et al. Quantitative sensory testing
profiles in chronic back pain are distinct from those in fibromyalgia. Clin
J Pain 2011;27:682–90.
[30] Hurtig IM, Raak RI, Kendall SA, et al. Quantitative sensory testing in
fibromyalgia patients and in healthy subjects: identification of subgroups.
Clin J Pain 2001;17:316–22.
[31] Gibson SJ, Littlejohn GO, Gorman MM, et al. Altered heat pain
thresholds and cerebral event-related potentials following painful CO2
laser stimulation in subjects with fibromyalgia syndrome. Pain 1994;
58:185–93.9
and ultra-late pain evoked potentials in fibromyalgia. Clin Neurophysiol
2001;112:1881–7.
[33] Racine M, Tousignant-Laflamme Y, Kloda LA, et al. A systematic
literature review of 10 years of research on sex/gender and experimental
pain perception - part 1: are there really differences between women and
men? Pain 2012;153:602–18.
[34] Walitt B, Nahin RL, Katz RS, et al. The prevalence and characteristics of
fibromyalgia in the 2012 National Health Interview Survey. PLoS One
2015;10:e0138024.
[35] Esearch R, Laske C, Stransky E, et al. Increased BDNF serum
concentration in fibromyalgia with or without depression or antide-
pressants. J Psychiatr Res 2007;41:600–5.
[36] Kerr BJ, Bradbury EJ, Bennett DL, et al. Brain-derived neurotrophic
factor modulates nociceptive sensory inputs and NMDA-evoked
responses in the rat spinal cord. J Neurosci 1999;19:5138–48.
[37] Heppenstall PA, Lewin GR. BDNF but not NT-4 is required for normal
flexion reflex plasticity and function. Proc Natl Acad Sci 2001;98:8107–
12.
[38] Lever IJ, Bradbury EJ, Cunningham JR, et al. Brain-derived neurotrophic
factor is released in the dorsal horn by distinctive patterns of afferent fiber
stimulation. J Neurosci 2001;21:4469–77.
[39] Malcangio M, Lessmann V. A common thread for pain and memory
synapses? Brain-derived neurotrophic factor and trkB receptors. Trends
Pharmacol Sci 2003;24:116–21.
[40] Yajima Y, Narita M, Narita M, et al. Involvement of a spinal brain-
derived neurotrophic factor/full-length TrkB pathway in the develop-
ment of nerve injury-induced thermal hyperalgesia in mice. Brain Res
2002;958:338–46.
[41] Zhao LY, Ye TH, Zhang YZ, et al. Combination of morphine with low-
dose naloxone for intravenous patient-controlled analgesia. Zhongguo
Yi Xue Ke Xue Yuan Xue Bao 2005;27:228–31.
[42] Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence
for a central sensitization in patients with fibromyalgia. Arthritis Rheum
2003;48:1420–9.
[43] de Zanette SA, Vercelino R, Laste G, et al. Melatonin analgesia is
associated with improvement of the descending endogenous pain-
modulating system in fibromyalgia: a phase II, randomized, double
dummy, controlled trial. BMC Pharmacol Toxicol 2014;15:40.
[44] Petzke F, Clauw DJ, Ambrose K, et al. Increased pain sensitivity in
fibromyalgia: effects of stimulus type and mode of presentation. Pain
2003;105:403–13.
[45] Staud R. Evidence of involvement of central neural mechanisms in
generating fibromyalgia pain. Curr Rheumatol Rep 2002;4:299–305.
[46] Staud R. Abnormal pain modulation in patients with spatially distributed
chronic pain: fibromyalgia. RheumDis Clin North Am 2009;35:263–74.
[47] Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron
2006;5:77–92.
[48] TsudaM, InoueK, SalterMW.Neuropathic pain and spinalmicroglia: a big
problem from molecules in “small” glia. Trends Neurosci 2005;28:101–7.
[49] Coull JAM, Beggs S, Boudreau D, et al. BDNF from microglia causes the
shift in neuronal anion gradient underlying neuropathic pain. Nature
2005;438:1017–21.
[50] Potvin S, Larouche A,Normand E, et al. DRD3 Ser9Gly polymorphism is
related to thermal pain perception andmodulation in chronic widespread
pain patients and healthy controls. J Pain 2009;10:969–75.
[51] Tarrago M da GL, Deitos A, Brietzke AP, et al. Descending control of
nociceptive processing in knee osteoarthritis is associated with intra-
cortical disinhibition: an wxploratory study. Medicine (Baltimore)
2016;95:e3353.
[52] Yarnitsky D. Conditioned pain modulation (the diffuse noxious
inhibitory control-like effect): its relevance for acute and chronic pain
states. Curr Opin Anaesthesiol 2010;23:611–5.
[53] Ossipov MH, Morimura K, Porreca F. Descending pain modulation and
chronification of pain. Curr Opin Support Palliat Care 2014;8:143–51.
